Generics Bulletin

Celltrion's Remsima SC Ready For Early 2020 Launch

By David Wallace 27 Nov 2020

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Datamonitor Healthcare

The evolving landscape of biosimilars

27 Nov 2020

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Generics Bulletin

Alberta Is Second Canadian Province To Switch To Biosimilars

By David Wallace 27 Nov 2020

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Pink Sheet

Germany Sets Direction Of Travel With New Biosimilar Guidelines

By Francesca Bruce 21 Sep 2020

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Chemist + Druggist Data

UK Sees PIP Codes Expand To Cover Hospital Drugs

By C+D Data 09 Sep 2020

Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital drugs.

Scrip

Scrip Preview Pharma Trends for 2020

06 Feb 2020

For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this  new decade.

Generics Bulletin

Teva Debuts US Rituximab At A 10% Discount

By David Wallace 08 Nov 2019

Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

Custom Intelligence Biosimilars Whitepaper

By Duncan Emerton 04 Nov 2019

If you’re looking at the opportunities to increase revenue and mitigate current and future threats by formulating the strongest biosimilars strategy, Informa’s Biosimilars Insights and Analysis Service is the tool you need.